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1 TABULAR OVERVIEW 
Study Title Efficacy of albendazole in decreasing Loa loa microfilaraemia 
Clinical Phase Non-regulatory study, Phase 2 (proof of concept) 
Study Rationale Loiasis is a filarial infection endemic in the rain forest of Subsaharan 
Africa.  In most cases, the infection is benign and does not result in 
disability or severe clinical symptoms.  It is not known to what extent 
infection is associated with fatigue, recurrent fever or perhaps arthritic 
pains or to what extent the eosinophilia seen in some infected subjects 
may contribute to endomyocardial fibrosis. 
Diethylcarbamazine is effective against Loa loa macrofilaria, but can cause 
serious complications such as meningoencephalitis, which is sometimes 
fatal.   
Ivermectin is very effective against microfilaria but can also be associated 
with serious and/or severe adverse events in subjects with high Loa loa 
microfilaria load (for more details see further below). Available data to date 
suggest that the risk of adverse events increases with L.loa microfilaria 
load.  Subjects with loa parasitemia  >8 100 mf/ml have an increased risk 
of developing reactions that result in functional impairment for at least 
several days compared to subjects with no detectable loa loa parasitemia 
(Gardon et al. 1997).  Serious neurological reactions including 
encephalopathies have been described in subjects with measured or 
estimated pre-ivermectin treatment loa parasitemia of >30 000 mf/ml 
(Ducorps et al. 1995, Gardon et al. 1997, MEC 2002, MEC 2003).  Most of 
the patients with serious neurological reactions recovered without any 
sequelae but some patients died or recovered with neurological and/or 
physical sequelae.   Thus, there is no safe treatment to treat or cure Loa 
loa infection.   
Ivermectin mass treatments of populations via community directed 
treatment (CDTI) in areas meso- or hyper-endemic for onchocerciasis is 
the cornerstone of onchocerciasis control programmes.  Similarly, yearly 
mass treatment with albendazole and ivermectin is the cornerstone of the 
efforts to eliminate lymphatic filariasis (LF) in Africa in areas where LF and 
onchocerciasis are coendemic.  Because of the risk of serious and/or 
severe adverse events associated with ivermectin treatment in subjects 
with loiasis, ivermectin mass treatment for onchocerciasis or LF is 
problematic in areas co-endemic for loiasis:   
In the absence of mass treatment suitable methods to identify subjects 
with high loa loa microfilaremia (LLM), the only way to eliminate the risk of 
the severe and/or serious adverse events during onchocerciasis control is 
to exclude areas with high prevalence and intensity of L. loa infection from 
standard ivermectin mass treatments.  In areas where onchocerciasis and 
loiasis are co-endemic, ivermectin treatment is initiated only once 
appropriate risk management measures have been put in place (Mectizan 
Expert Committee and The Technical Consultative Committee, 2004).  LF 
control programs are not being expanded into areas co-endemic with 
loiasis.   
Thus, a safe treatment reducing LLM would not only benefit Loa loa 
infected subjects by reducing loiasis related signs and symptoms and the 
probability of severe long term sequelae of the infection, but if sufficiently 
effective to reduce LLM below the level associated with risk of serious 
and/or severe adverse events prior to treatment with ivermectin (alone or 
in combination with albendazole) could prevent the occurrence of these 
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AEs in Loa loa infected subjects with onchocerciasis and/or lymphatic 
filariasis.   
A safe treatment would reduce LLM not by killing the microfilaria but rather 
by preventing the generation of new microfilariae so that LLM is reduced 
slowly as the microfilariae reach the end of their natural life span.   
Previous experience with albendazole suggests that albendazole does not 
kill Loa loa microfilariae, but rather exerts a macrofilaricidal or macrofilaria 
sterilizing effect.  The short term albendazole treatment regimens 
evaluated to date have not resulted in a sufficient and sustained reduction 
of Loa loa microfilaremia.  The time course of LLM following the treatment 
regimens evaluated to date, suggests that multiple administration of this 
drug every two months several times may achieve a significant 
progressive slow decrease of Loa parasitemia.   
This trial will evaluate the effect of 800 mg albendazole administered twice 
or 6 times every two months on LLM. 
Trial Design Randomized, double-blind, placebo-controlled, field trial 
Approximate Duration 
of Subject 
Participation  
Up to 2 months between initiation of screening and treatment  
18 months between first treatment and last follow up.   
Approximate Duration 
of Study 
21 months, including  
2 months between initiation of screening and enrolment 
19 months of treatment and follow up period across all subjects 
Study Objective(s) Primary objective 
Evaluate the efficacy of two different albendazole treatment regimens in 
sustainably reducing L. loa microfilarial (mf) load in subjects with 
pretreatment levels >15000 mf/ml 
Secondary objective 
Assess the safety of these treatment regimens in the study subjects 
Diagnosis and Main 
Criteria for Inclusion 
18-65 year old males and non-pregnant females with parasitologically 
confirmed Loa loa parasitaemia of >15000 microfilaria/ml who are 
otherwise healthy 
Main Criteria for 
Exclusion 
Subjects who meet ANY of the following criteria will be excluded from the 
study 
- Treatment with a benzimidazole during the last 12 months 
- Self-reported allergy to benzimidazoles. 
- Pregnancy  
- Clinical signs and symptoms and laboratory evidence of intestinal 
helminths 
- Any serious underlying medical condition  
- Past or current history of neurological or neuropsychiatric disorders 
- Clinical and/or laboratory evidence of significant liver disease, kidney 
disease or anaemia or any other condition that in the investigator's 
judgment should exclude the subject from the study. 
Number of Subjects 60 subjects, including 20 treated with placebo, and 20 each treated with 
one of the two albendazole dosing regimens 
Number of Study 
Centers Single center study 
Concomitant None 
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Treatment 
Study Treatment Albendazole tablets (200 mg) and matching placebo 
Administration: 800 mg albendazole orally every two months 0 (group 1, 
placebo), 2 (group 2, treatment regimen 1) or 6 times (group 3, treatment 
regimen 2).   
Albendazol has a well-established excellent safety profile which allows it to 
be administered without medical supervision not only to infected, but also 
to uninfected subjects during the mass treatment of populations living in 
areas endemic for LF. 
Efficacy Evaluation L. loa microfilaremia determined via calibrated blood smears (CBS) pre-
treatment and 2, 4, 6, 8, 10, 14 and 18 months after the first treatment.  
Blood samples for CBS will be obtained at around the same time between 
11:00 and 15:00 o'clock to account for the diurnal variation of L.loa counts 
in the blood.   
Safety Evaluation On the day of treatment as well as 3 and 7 days after each treatment 
subjects will be evaluated clinically and for self-reported adverse events. 
On the day of the next treatment, subjects will be asked for adverse events 
experienced since day 7 after the previous treatment.  Laboratory tests will 
be performed at screening and if indicated based on the results of the 
clinical investigation or based on subject reported AEs. 
Statistical Analysis The proportion of subjects with a sustainable (≥ 4 months) reduction of 
LLM by ≥50% of the baseline value by treatment group across all subjects 
and by initial microfilaria load, will be compared with the Chi-squared test.   
Comparison of L. loa mf/ml between treatment groups at each time point 
with non-parametric tests due to non-normal distribution of mf loads. 
General linear model for analysis of the evolution of microfilaria load in 
time in each treatment group. 
Rationale for Number 
of Subjects 
A positive response in a subject is defined as a drop in LLM from baseline 
values by ≥50% lasting at least 4 months. Assuming that in the population 
less than 1/106 subjects will have a positive response if randomized to the 
placebo group and at least 50% of the subjects will have a positive 
response if randomized to the 6 dose albendazole treatment regimen, a 
sample size of 16 subjects in each treatment arm will provide at least 90% 
power to detect statistically significant (two-sided α=0.025) differences 
between the placebo group and the 6 dose albendazole treatment group.  
The same assumptions were made for the 2 dose albendazole treatment 
regimen so that the same power and sample size considerations apply to 
the comparison between placebo and the 2 dose albendazole treatment. 
An alpha value of 0.025 was chosen since two comparisons (placebo vs. 2 
doses of albendazole, placebo vs. 6 doses of albendazole) will be 
performed.  Based on prior experience, a drop out rate of approximately 
20% is expected, resulting in a sample size of 20 subjects for each of the 
three treatment arms. 
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2 STUDY FLOW CHART 
  Group 1 (20 subjects) Group 2 (20 subjects) Group 3 (20 subjects) 
Month Day Treatment Examination Treatment Examination Treatment Examination 
M-2 to 0 NA Village information,  
Informed Consent for initial Screening, Initial Screening 
   - CBS  - CBS  - CBS 
M-2 0 NA Informed Consent for the remainder of the study, if applicable 
Final subject qualification 
   - Q-CE 
- PT 
- LV 
 - Q-CE 
- PT 
- LV 
 - Q-CE 
- PT 
- LV 
M0 NA Final subject selection, randomization 
Baseline data acquisition 
   - CBS 
  
 - CBS  - CBS 
M0 D 0 Placebo AEs Albendazole AEs Albendazole AEs 
 D 3 - AEs - AEs - AEs 
 D 7 - AEs - AEs - AEs 
M2 D 60* Placebo - CE 
- CBS 
- PT 
- AEs 
Albendazole - CE 
- CBS 
- PT 
- AEs 
Albendazole - CE 
- CBS 
- PT 
- AEs 
 D 63 - AEs - AEs - AEs 
 D 67 - AEs - AEs - AEs 
M4 D 120* Placebo - CE 
- CBS 
- PT 
- AEs 
Placebo - CE 
- CBS 
- PT 
- AEs 
Albendazole - CE 
- CBS 
- PT 
- AEs 
 D 123 - AEs - AEs - AEs 
 D 127 - AEs - AEs - AEs 
M6 D 180* Placebo - CE 
- CBS 
- PT 
- AEs 
Placebo - CE 
- CBS 
- PT  
- AEs 
Albendazole - CE 
- CBS 
- PT 
- AEs 
 D 183 - AEs - AEs - AEs 
 D 187 - AEs - AEs - AEs 
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  Group 1 (20 subjects) Group 2 (20 subjects) Group 3 (20 subjects) 
Month Day Treatment Examination Treatment Examination Treatment Examination 
M8 D 240* Placebo - CE 
- CBS 
- PT 
- AEs 
Placebo - CE 
- CBS 
- PT 
- AEs 
Albendazole - CE 
- CBS 
- PT 
- AEs 
 D 243 - AEs - AEs - AEs 
 D 247 - AEs - AEs - AEs 
M10 D 300* Placebo - CE 
- CBS 
- PT 
- AEs 
Placebo - CE 
- CBS 
- PT 
- AEs 
Albendazole - CE 
- CBS 
- PT 
- AEs 
 D303 - AEs - AEs - AEs 
 D 307 - AEs - AEs - AEs 
M14 D 420** - - CBS 
- AEs 
- - CBS 
- AEs 
- - CBS 
- AEs 
M18 D540** - - CBS 
- AEs 
- - CBS 
- AEs 
- - CBS 
- AEs 
AEs:  Adverse events monitoring, laboratory evaluations as clinically indicated 
CBS:  Calibrated Blood Smear 
CE:  Clinical examination during follow up, laboratory evaluations as clinically indicated 
LV:  Laboratory values (alanine aminotransferase, aspartate aminotransferase, creatinine, 
haemoglobin, complete blood count) 
PT:  Pregnancy test 
Q-CE Clinical evaluation for exclusion criteria, laboratory evaluations 
* Day 60, 120, 180, 240, 300: each ±3 days 
** Day 420, 540: each ± 1 week 
 
3 RATIONALE AND BACKGROUND 
Loiasis is a parasitic infection endemic in the rain forest areas in Sub-saharan Africa caused by 
the filarial nematode Loa loa.  The adult worms (females up to 70 mm long with a diameter of 
around 0.5 mm, males smaller) migrate through the subcutaneous tissues and into the 
conjunctiva, which has given the disease in many areas the local name 'eye worm'.  The 
microfilaria (up to 300 µm x 8 µm) are present in the peripheral blood during the day time (see 
Figure 1).   
Clinical manifestations include 'Calabar swelling', a hypersensitivity response to the antigenic 
material released by the macrofilaria, which lasts a few hours or days and is usually painless, 
itching, swelling of lids with itching and pain, and hydrocele caused by adult worms in the 
scrotum.  In most cases loiasis is a relatively benign disease with a good prognosis and many 
patients do not have defined signs or symptoms for years before the infection is diagnosed 
(primarily via the Calabar swelling or the 'eye worm').  It is not know to what extent infection with 
Loa loa causes fatigue, recurrent fever and perhaps arthritic pains.  Loiasis appears to be rarely 
associated with disability or serious ill health.  However, since loiasis can be associated with 
significant and sustained eosinophilia, it may be one of the filarial infections that contributes to 
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endomyocardial fibrosis due to the effects of eosinophils on the heart (Parry et al. 2004, Duke 
1991, Ukety, personal communication). Loa loa infected patients frequently complain about 
itching, swelling of the face, the lip, or the legs, the eye during the passage of adult Loa loa, 
asking for a curative treatment. 
However, there is currently no safe treatment to reduce or eliminate Loa loa infection. 
Diethylcarbamazine (DEC) is effective against Loa loa macrofilaria, but can cause serious 
complications such as meningoencephalitis which is sometimes fatal (Duke 1991).   
Ivermectin is an effective Loa loa microfilaricide, which results in a very rapid around 80-90% 
reduction of microfilaraemia within around 3 days of treatment (Richard-Lenoble et al. 1988, 
Carme et al. 1991, Chippaux et al. 1992, Martin-Prevel et al. 1993).  The initial studies 
conducted on the effect of ivermectin in small numbers of subjects with relatively low levels of 
Loa loa microfilaremia showed that ivermectin was well tolerated in these subjects.  However, 
when large numbers of Loa loa infected subjects were treated with ivermectin (Mectizan) within 
the framework of onchocerciasis control programmes, it was found that ivermectin treatment of 
subjects heavily infected with Loa loa can result in serious adverse events (SAEs), including 
encephalopathies (see e.g. Figure 1).   
Table 1 summarizes data on serious neurological adverse events reported in clinical studies 
and/or during the implementation of ivermectin mass treatment and provides the pretreatment 
Loa loa microfilaremia (LLM). 
Table 1 Overview of severe or serious neurological events reported in the literature 
Adverse event(s) 
(Comments) 
Pre-Tx LLM 
(mf/ml) 
Pre Tx LLM count based 
on 
Source 
Grade 2 coma 
(1/26 subjects with >30000mf/ml) 
163000  Pretreatment measurement Ducorps 
et al. 1995 
Serious neurological reaction (disorders of 
consciousness, coma, incontinency, sensory 
deficits, hypertonia) 
(2/>3242 subjects with LLM including 18 with 
geometric mean LLM of 83448 mf/ml, 2/160 
subjects with LLM >30000) 1 
50502  
152940 
Pretreatment measurement Gardon et 
al. 1997 
PLERM 2 36000  Extrapolated from mean 
post-treatment level 
MEC 2002 
1 17877 subjects were treated.  Loa loa blood microfilaremia was evaluated in 5500 (31%) subjects, including 
18/20 with serious neurological reaction, of whom 58% (3242) were Loa loa positive (Gardon et al. 1997) 
and 160 (2.9%) had LLM >30000 mf/ml pre-treatment (Boussinesq et al. 1998). 
2 PLERM: Probable or possible Loa loa encephalopathy related to treatment with Mectizan. Loa loa 
encephalopathy related to treatment with Mectizan: Encephalopathy (without seizures, usually with fever) in 
a person previously healthy and without another underlying cause for emcephalopathy, onset of progressive 
CNS symptoms and signs within 7 days of treatment with ivermectin, illness progressing to coma without 
remission with assessment of probability of relationship to Mectizan treatment based on availability of LLM 
data: Probable if peripheral blood L.loa >10000 mf/ml pretreatment or >1000 mf/ml within 1 month post 
treatment or >2700 mf/ml within 6 months of treatment, and/or L.loa microfilarae in the CSF.  Possible if 
semi-quantiative or non-quantitative positive (i.e. +, +, +++) L.loa  microfilariae in pheripheral blood within 1 
month post treatment.  
 
The relatively low number of subjects with high LLM for which reliable LLM and adverse event 
data are available from prospective studies (Ducorps et al. 1995, Gardon et al. 1997) and the 
likely underreporting of SAEs and lack of pre-treatment LLM values from mass treatment with 
ivermectin (MEC 2002, Twum-Danso, 2005), do not allow to definitively determine the minimum 
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pre-ivermectin treatment LLM that puts subjects at risk for development of serious and/or severe 
adverse events.   
Minimum levels proposed based on the available data include:   
• > 50000 mf/ml results in an odds ratio of >1000 for serious adverse reactions (including non-
neurological reactions, Gardon et al. 1997) 
• > 50000 mf/ml for encephalopathy (MEC 2002) 
• > 50000 mf/ml for disorders of consciousness (Boussinesq et al. 2003) 
• > 36000 mf/ml (approximately) for PLERM (MEC 2002) 
• > 30000 mf/ml, probability of >0.007 for development of serious adverse reactions, whether 
neurological or not (Boussinesq et al. 2003) 
A pre-treatment LLM of > 10000 mf/ml as the criterion for the diagnosis of probable LERM was 
established in 1995 by a consultation and not revised to date (MDP, 1996).   
Analysis of the most comprehensive prospectively obtained data available to date on the 
adverse reactions to ivermectin in subjects with LLM quantitated prior to ivermectin treatment 
resulted in the conclusion that the relative risk of developing any type of adverse reaction 
resulting in functional impairment requiring assistance for everyday natural functions and 
household activities for at least several days ('marked reactions') is statistically significantly 
higher in subjects with >8100 mf/ml than in subjects without detectable LLM (Gardon et al. 
1997).   
Disease control programmes for onchocerciasis rely on the community directed mass treatment 
of ivermectin (CDTI).  During CDTI, subjects living in areas hyper- or mesoendemic for 
onchocerciasis are being administered a single dose of ivermectin without the presence of 
health care personnel and independent of whether or not they are infected.  This is possible 
because of the excellent safety profile of ivermectin in healthy subjects and subjects infected 
with Onchocerca volvulus and not co-infected with Loa loa.   
Mass treatment procedures are also in place for lymphatic filariasis (LF) control.  The objective 
of the global program for the elimination of lymphatic filariasis (GPELF) is to interrupt 
transmission of the disease by treating the entire at risk population with a single administration 
of two drugs given simultaneously once yearly.  Where onchocerciasis and LF are co-endemic 
in Africa, mass treatment uses ivermectin combined with albendazole.  In areas in Africa and in 
Asia where lymphatic filariasis is not co-endemic with onchocerciasis, albendazole is combined 
with DEC.  The Safety Review Committee which reviewed the adverse event data obtained 
during active surveillance in 12 countries instituting mass drug administration (MDA) for LF 
control decided that there was no need for further active surveillance for adverse events during 
MDA (WHO, 2003). 
The risk of serious and /or severe adverse events among Loa loa infected subjects treated with 
ivermectin restricts onchocerciasis disease control efforts in two ways: 
• As per the recommendations of the MectizanR Expert Committee (MEC) and the Technical 
Consultative Committee of the African Programme for Onchocerciasis Control (APOC), 
mass treatment in areas with high prevalence or intensity of infection with L. loa requires 
considerable additional operational investment (education of target population, training and 
preparation of medical personnel on SAE management, equipment of health care facilities 
for SAE treatment, employment of medical personnel for population surveillance).  This 
requires substantial additional resources (Mectizan Expert Committee and The Technical 
Consultative Committee, June 2004) which are not available for further expansion of 
onchocerciasis control. 
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• The fear of serious and/or severe adverse events leads to a reduced participation of the 
population in CDTI.  As high a population coverage as possible is, however, not only in the 
interest of individual subjects with onchocerciasis, but also in the interest of the community 
and region since it is the key to reduction of disease transmission. 
The impact on lymphatic filariasis (LF) control efforts is even greater:  
• Following the experiences and analysis of SAEs during onchocerciasis control, and a risk-
benefit assessment, it was decided not to move LF control into areas co-endemic with 
loiasis.  Thus, the progress of LF control is completely stalled in areas co-endemic for LF 
and loiasis.   
A treatment reducing the L. loa microfilaremia well below the currently identified risk level and 
safe enough to be administered in a community directed way prior to CDTI or MDA for LF could 
allow standard CDTI to proceed and LF control to be instituted in Loa loa co-endemic areas.  
However, no safe treatment that reduces L. loa microfilaremia is available.   
The mechanism by which ivermectin treatment in subjects with high LLM leads to serious 
neurological adverse events is unknown.  Based on the analysis of the symptoms observed, 
prior experience with DEC treatment associated encephalopathies in subjects with high LLM 
and the knowledge of Mazzotti reactions following ivermectin or DEC treatment of subjects with 
onchocerciasis, three potentially concomitant mechanisms have been proposed: (1) obstruction 
of the cerebral microcirculation in consequence of massive amounts of paralyzed or dead Loa 
loa microfilariae, (2) penetration of live microfilaria into the brain tissue, (3) inflammatory 
processes in the brain (Boussinesq 2003).   
Independent of the mechanism and the presence and relative importance of potential co-factors, 
serious neurological reactions following ivermectin treatment have to date been observed only 
in subjects with high LLM (Table 1, Figure 1).  Consequently, a safe treatment for reducing LLM 
should have no or very inefficient Loa loa microfilaricidal activity and reduce LLM exclusively or 
primarily through a macrofilaricidal or macrofilaria sterilizing effect so that the reduction in LLM 
occurs slowly primarily through Loa loa microfilaria reaching the end of their natural life span 
(unknown, but estimated at up to 6 months based on data from human Loa loa infected 
monkeys, Duke 1960) and not being replaced.  Based on prior data on the effect of albendazole 
on LLM (see further below and Table 2), albendazole may have the efficacy and safety profile 
required.  
 
Albendazole is a benzimidazole.  Benzimidazoles are broad-spectrum anthelmintics with a high 
therapeutic index whose primary site of action are the microtubules via inhibition of tubulin 
polymerization.   
Due to its low aqueous solubility, oral bioavailability of albendazole is poor (<5%).  Following 
absorption, albendazole is quickly metabolized into the active metabolite albendazole 
sulphoxide which is further metabolized to albendazole sulfone and other primary oxidative 
metabolites.   
Urinary excretion of albendazole sulfoxide is a minor elimination pathway, accounting for less 
than 1% of the dose recovered in urine.  Consequently, while pharmacokinetic studies in 
patients with impaired renal function have not been conducted, it is unlikely that clearance of 
albendazole and its primary metabolite, albendazole sulfoxide, would be altered in these 
patients (Glaxo Smith Kline 2001).  
After administration with a fatty meal several fold higher Cmax and four fold higher AUC0-36h 
values were obtained than in subjects who took the same dose in the fasting state.  A single 800 
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mg dose of albendazole administered with a fatty meal resulted in an albendazole sulphoxide 
Cmax of 1943 ± 403 µg/L, and AUC0-36h of 20992 µgh/L (Awadzi et al. 1994). 
Pharmacokinetic data from subjects infected with O. volvulus administered 200 mg albendazole 
q6h for 3 days or 200 mg albendazole q4h for 3 days suggest that the major fraction of the 
albendazole sulphoxide detectable during the first three days after the first dose is due to the 
doses administered during the first day (Awadzi et al. 1994).  This is consistent with data that 
show that following 4 weeks of treatment with 200 mg albendazole TID, albendazole sulfoxide 
concentration was 20% lower than during the first half of the treatment period  (Glaxo Smith 
Kline, 2001).  
The safety data from use of albendazole for anthelminthic treatment from clinical trials as well 
as the published literature and/or spontaneously reported to the manufacturer were recently 
reviewed (Horton 2000).  
After dosing for ≤3 days (400 mg single dose, 400 mg QD for 3 days or 800 mg single dose), 
the incidence of adverse events among 22810 subjects in different clinical trials for treatment of 
intestinal helminths did not exceed 0.386% for any individual type of adverse event.  Different 
types of gastrointestinal effects were the most frequent AEs with a total incidence across all 
types of <1%.  Laboratory value based adverse events included leucopenia (0.044%), raised 
liver enzymes (0.035%), low red cell count and proteinuria (0.009% each), anemia and raised 
blood urea (0.004% each).  These symptoms are common in the communities with helminth 
infections so that drug relationship of the AEs is hard to assess.  The only study that compared 
albendazole and placebo treatment in sufficient number of patients did not find significant 
differences between the two treatment arms (Horton 2000). 
In contrast to the very short treatments used for antihelminth or LF indication, and planned in 
this study (single 800 mg dose, every 2 months up to 6 times), long term daily use of up to 800 
mg/day as for hydatic disease (recommended dose regimen: three 28 day cycles of 15 
mg/kg/day up to 400 mg BID, with 14 days between cycles) is associated with a higher 
frequency of AEs.  Liver and biliary AEs were the most frequent AE observed in 10.8% among 
3282 subjects treated for hydatid disease (Horton 2000).  Mild to moderate increases in 
transaminase levels at least possibly or probably related to albendazole were reported for 
15.6% of hydatid disease patients in the GSK safety data base.  Upon discontinuation of 
albendazole treatment, the transaminase values returned to normal.  For subjects treated for 
hydatid disease or for neurocysticercosis (treatment regimen 15 mg/kg/day up to 400 mg BID 
for 8-30 days) liver function tests before start of each treatment cycle and at least every 2 weeks 
during treatment and discontinuation of treatment if enzyme levels increase significantly is 
recommended.  Patients with abnormal liver function tests prior to initiation of albendazole 
treatment should be carefully evaluated since the drug is metabolized by the liver and has been 
associated with hepatotoxicity in a few patients.  (GSK 2001).   
Among 11 men with loiasis who received 200 mg albendazole BID for 21 days none had 
elevations of alanine aminotransferase or aspartate aminotransferase or changes in 
haematocrit.  Adverse events included myalgia (40%), arthralgia (50%), pruritus (20%) 
(observed in the placebo group in 36%, 36% and 36%, respectively), calabar swelling (20%) 
and dizziness (10%) (Klion et al 1993).   
For the hydatic disease patients , blood counts monitoring is recommended by the manufacturer 
at the start of each 28 day cycles and every 2 weeks during each 28-day cycle because 
reversible reductions in total WBC have been observed in <1% of patients and 
granulocytopenia, agranulocytosis or pancytopenia in rare cases (GSK 2001). 
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There is one case report from physicians in Switzerland on an encephalopathy in a subject with 
loiasis from Cameroon treated with albendazole in Switzerland (Blum et al. 2001).  The PI and 
TDR consulted with clinical experts (involved in the analyses of encephalopathy cases observed 
in L.loa - O. volvulus co-infected patients and in treatment of subjects with numerous 
antihelminths, including albendazole), on the probability of this encephalopathy being causally 
related to the albendazole treatment this subject received and consequently on safety 
monitoring in this study.  There was unanimous agreement that the probability that this 
encephalopathy was causally related to L.loa infection was extremely remote since (1) the L. loa 
microfilariaemia was extremely low (152 mf/ml), (2) the medical history of the subject provided 
likely causes (diabetic with antecedent unexplained neurologic signs) and (3) the time course of 
the symptoms is completely inconsistent with the slow effect of albendazole on microfilarial 
levels.  The experts advised that the safety monitoring planned in this protocol is adequate.   
Previous trials with albendazole (Table 2) have shown that administration of albendazole over a 
short period of time (one to three days) does not result in a significant, sustained reduction of 
LLM.  Administration over 21 days was more effective, but is not feasible within mass 
treatments.  Furthermore, the study evaluating 21 days of albendazole treatment did not include 
subjects with more than 30000 mf/ml.   
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Table 2 Overview of effect of albendazole treatment on Loa loa microfilaremia 
Albendazole regimen  
(number of subjects) 
Pre-Tx LLM (mf/ml) 
Time of measurement 
Range (Geom. Mean) 
Efficacy (% geometric mean preTx 
values) 
Adverse events 
 
200 mg BID, 21 days (11)1 
 
 
 
Placebo BID, 21 days (12) 
11:30-14:30 
385 - 20200 (2369) 
 
 
 
236 - 27500 (3119) 
 
- 70%-20% over 3 mos post Tx start 
- 20% at 6 mos 
 
 
- 37%-192% over 3 mos post Tx start 
- 84% preTx at 6 mos 
 
Myalgia, arthralgia, 
pruritus, increased 
appetite, dizziness, 
calabar swelling 
Myalgia, arthralgia, 
pruritus, increased 
appetite 
 
600 mg, single dose (23)2 
 
 
 
 
Mebendazole, 100 mg 
BID, 3 days (24) 
11:00 - 13:00 
7 - 1377 (180) 
 
 
 
 
3 - 5535 (195) 
 
- 60%-125% over 3 mos post Tx start 
- 60% at 6 mos 
- 57% at 10 mos 
 
- 70%-132% over 3 mos post Tx start 
- 93% at 6 mos 
- 86% at 10 mos 
No adverse events 
reported 
 
400 mg, QD, 3 days  (48)3 
- 180 days FU (37) 
- placebo (28) 
- 180 days FU (27) 
 
 
Placebo, QD, 3 days (51) 
- 180 days FU (40) 
- 400 mg, QD, 3 days (36) 
- 180 days FU (28) 
10:00 - 15:00 
100 - 33837 (2550.3) 
 
 
 
 
 
164.3 - 24050 (5507.9) 
 
ALB:  90%-70% over 3 mos post Tx 
 90% at 6 mos 
Plac:  105%-95% over 3 mos post Tx 
 >120% at 6 month 
 
Plac:  98%-110 over 3 month post Tx 
 120% at 6 mos 
ALB:  95%-65% over 3 mos post Tx 
 90% at 6 mos 
No difference 
between 
albendazole and 
placebo treatment 
 
400 mg, BID, 3 days (47) 4 
 
 
 
 
 
Multivitamin 
11:00-15:00 
260 - 54180 (3800) 
Subgroup of 12 with 
LLM >8000 
8460 - 54180 (18594) 
 
 
240-46780 (3467) 
Subgroup of 14 with 
LLM>8000 
8640-46780 (15558) 
All subjects 
71%-82% over 3 mos post Tx 
91%-81% 6-9 mos post Tx 
> 8000 PreTx 
94-53% pre Tx over 3 mos post Tx 
104%-89% 6-9 mos post Tx 
 
All subjects:  
98-83% over 3 mos post Tx 
91-107% 6-9 mos post Tx 
>8000 preTx 
92-74% over 3 mos post Tx 
82-114% 6-9 mos post Tx 
 
Itching, abdominal 
pain, diarrhea 
Increased ALT/AST 
on day 5 
 
 
Itching, diarrhea 
1 Klion  et al. 1993, 2 Kamgno, Boussineq 2002, 3 Tabi et al. 2004 (% in efficacy cell approximated from 
Figure 2 in the publication). 4 Tsague-Dongmo et al. 2002 
 
The time course in LLM seen in these studies, comparison of the effect of different doses 
evaluated as well as significant intra-individual variation in the effect of a single albendazole 
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dose, suggest that multiple exposure of the Loa loa macrofilaria with albendazole at two month 
intervals may have the desired effect on the reproductive capacity of the macrofilaria.  The 
safety data available show that a single dose of 800 mg has an excellent safety profile, 
consistent with other data on the safety of single doses of albendazole (see above). 
This study will evaluate the effect of an albendazole dose of 800 mg, administered every two 
months 2 or 6 times, respectively. 
4 STUDY GOAL, OBJECTIVES AND EXPECTED OUTCOMES 
The goal of this study is to evaluate whether one or both of the evaluated albendazole treatment 
regimens are sufficiently effective in reducing L.loa parasitemia and safe to potentially be 
qualified as candidate for mass treatment for the reduction of LLM.  
The primary objective of this study is to evaluate the efficacy of two different albendazole 
treatment regimens in sustainably reducing L. loa microfilarial load in subjects with high pre-
treatment microfilaremia. 
The secondary objective is to assess the safety of these treatment regimens in the study 
subjects in terms of frequency of adverse events by type and severity.   
In case this proof of principal study shows that one or both of the two albendazole treatment 
regimens, but not the placebo treatment reduce microfilaria counts sustainably (i.e. for a period 
of at least 4 months) by ≥ 50% of pretreatment values, and the safety profile is, as expected 
based on the prior experience with albendazole, consistent with the requirements for mass 
treatment, the results will be discussed with the stake holders to decide on further studies to be 
conducted. 
5 STUDY DESIGN 
5.1 Overview 
This is a randomized, double blind, placebo controlled field-based study of subjects infected 
heavily with L. loa who are otherwise of good health and live in an area not endemic for 
onchocerciasis or lymphatic filariasis.  An area not co-endemic with onchocerciasis was 
selected because all areas endemic for onchocerciasis in Cameroon are either already 
conducting or are initiating CDTI and ivermectin treatment reduces Loa loa microfilaremia (see 
section  3) making it impossible to find subjects with high LLM.  Furthermore, since ivermectin is 
an effective Loa loa microfilaricide, the effect of albendazole on LLM can only be evaluated if 
during the study period the subjects do not take ivermectin.  Enrolling subjects co-infected with 
Onchocerca volvulus in this study would mean that for the around 20 months duration of the 
study, these subjects would be deprived of the benefit of ivermectin treatment, which should be 
administered at least on a yearly to maintain Onchocerca volvulus microfilaria levels below 
those where symptoms and potentially disease progression occur.   
Selection of an area endemic for lymphatic filariasis and highly endemic for loiasis is not 
possible, because the data from the recently conducted survey for the distribution of lymphatic 
filariasis in Cameroon have been deemed to be unreliable.   
While the medical need for a LLM reducing treatment is greatest among populations living in 
areas co-endemic for loiasis and onchocerciasis and/or lymphatic filariasis (see section  3), 
populations living in areas endemic only for loiasis will also benefit from a treatment that safely 
reduces LLM and thus presumably reduces the signs and symptoms and potentially long-term 
sequelae of loiasis.  Among these populations particularly the subjects with high Loa loa 
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microfilaremia, such as those selected for this study, will benefit from the qualification of an LLM 
reducing treatment.   
60 males and non-pregnant females between 18 and 65 years with an LLM of >15 000 mf/ml 
will be enrolled in this study and randomized by pretreatment LLM to one of three treatment 
regimens: 
• Placebo Control (Group 1)  
these subjects will receive 6 oral doses of placebo, one every two months 
• 2 doses of albendazole (Group 2) 
these subjects will receive 2 oral doses of albendazole (800 mg)  2 months apart, followed 
by four doses of placebo every two months 
• 6 doses of albendazole (Group 3) 
these subjects will receive 6 oral doses of albendazole (800 mg), one every two months 
Prior to each administration, subjects will undergo a pregnancy test, if applicable, as well as a 
clinical examination, quantitation of L.loa parasitemia and be asked about any adverse events 
since the last visit.  If they show signs and symptoms of intestinal helminths, the stool will be 
examined.  If clinically indicated or indicated based on the report of adverse event(s) by the 
subject, a full blood count and laboratory evaluations will be performed as appropriate. Follow 
up for adverse events will be conducted at the day of treatment, day 3 and day 7 after each 
treatment as well as at the next treatment and/or efficacy follow up visit. 
Efficacy will be evaluated via microfilaria counts in a calibrated blood smear obtained prior to 
each administration as well as 4 months and 8 months after the last dose was administered.  To 
account as much as possible in a field based study for the effect of the diurnal periodicity of the 
L. loa counts in the peripheral blood (), the calibrated blood smear samples will be obtained 
between 11:00 and 15:00 and at around the same time of day in each village. 
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Figure 1 Loa loa microfilaremia counts and diurnal change in Loa loa infected subjects treated 
with ivermectin in Cameroon 
Non-CNS SAE: serious adverse events not affecting the central nervous system. 
 
 
Following unblinding of the data and completion of the analysis, the villages will be informed 
about the outcome of the trial and what consequences can be drawn for further studies to 
qualify albendazole for treatment of loiasis.   
5.2 Primary endpoint 
The primary endpoint will be the proportion of subjects in whom there is a sustainable (≥ 4 
months) reduction in microfilaremia by ≥50% of pretreatment values at any time point post the 
first drug administration by treatment group.   
5.3 Secondary endpoints 
• Proportion of subjects whose microfilaria counts have been sustainably reduced to <8100 
mf/ml by treatment group 
• % of reduction in microfilaremia (range, median, Williams geometric mean) at each time 
point by treatment group by microfilaria level pretreatment and gender 
• Microfilaria loads at each time point in each treatment group, compared by non-parametric 
tests because of the non-normal distribution of the Loa microfilaremia. 
• Evolution of microfilaria counts in time 
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• Type, frequency and severity of adverse events (all adverse events and separate only those 
with a reasonable probability of relationship with study drug, see section  8.5).   
6 METHODOLOGY 
6.1 Selection of study population and acquisition of baseline data 
The trial will be carried out in the South and Central provinces of Cameroon. Subjects will be 
recruited from villages in the Nyong and Soo and Mvila division. These areas are endemic for 
loiasis but without onchocerciasis and without lymphatic filariasis.   
 
The schematics below provides an overview of the selection of the study subjects. 
 
 * A general medical consultation will be offered to those who have medical complaints (including villagers 
who want medical consultation but do not want to participate in the preliminary survey for LLM) and some 
drugs will be available to treat subjects with any ailment that is amenable to treatment. Villagers will be 
referred to a health center if the ailment is not amenable to treatment by the study team.  These 
examinations will not yield any data for the study. 
 
6.1.1 Inclusion criteria 
Subjects who qualify for this study have to fulfill ALL of the following criteria: 
• 18 to 65 year old male or female.   
Discussion of study with village 
(village elders, village meeting)
Preliminary Survey (appr. 2500 subjects, 18-65 
yrs, male or self-reported non-pregnant female)
Informed consent for determination of filaremia
Finger prick for L.loa filaremia determination*
Not eligible for study:
Subject will be provided 
explanation for ineligibility and 
referred to hospital if necessary
Final subject qualification
Informed Consent for remainder 
of the study
Evaluation of exclusion criteria
<15000 mf/ml and/or disease 
requiring referral to hospital
>=15000 mf/ml
Not eligible for study:
Subject will be provided 
explanation for ineligibility and 
referred to hospital if necessary
Final subject selection 
and randomization
Meets =1 exclusion criterion
Meets all 
eligibility criteria
Subject not selected will be given 
an explanation
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• L. loa microfilaremia >15 000 mf/ml as determined by calibrated blood smear. 
• Do not plan on moving out of the area over the next two years. 
• Given informed consent (written, witnessed, signed or thumb printed). 
6.1.2 Exclusion criteria 
Subjects who meet ANY of the following criteria will be excluded from the study 
• Treatment with a benzimidazole during the last 12 months 
• Self-reported allergy to benzimidazoles. 
• Pregnancy, assessed by urine pregnancy test (β-HCG) before each treatment in all women 
of child-bearing potential.  
• Clinical signs and symptoms and laboratory evidence of intestinal helminths 
• Any serious underlying medical condition  
• Past or current history of neurological or neuropsychiatric disorders 
• Clinical and/or laboratory evidence of significant liver disease, kidney disease or anaemia or 
any other condition that in the investigator's judgment should exclude the subject from the 
study. 
6.1.3 Conduct of screening 
Based on the prevalence of L. loa in these areas and the inclusion / exclusion criteria, it is 
estimated that between 2% and 5% of the population is eligible for this study.  Thus in order to 
recruit 60 subjects for the study up to around 2500 subjects need to be screened.  It will be 
necessary to conduct screening in around 25 communities, considering the average of around 
100 18-65 year old persons per community. 
Given the large number of subjects to be screened, screening will be conducted in two steps: 
1. Preliminary survey among 18-65 year male villagers and 18-65 year old female villagers 
who present themselves as not pregnant  to identify subjects who fulfill the LLM inclusion 
criterion 
2. Definitive subject identification by assessment of the presence of any of the exclusion 
criteria among subjects with > 15000 mf/ml based on the preliminary survey. 
6.1.3.1 Village information about study and village focal point 
Prior to the initiation of the preliminary survey, each village in the study area will be visited to 
inform the villagers about the objectives and procedures of the study, to inform them about and 
discuss with them the risks and benefits of study participation and to answer any questions they 
may have. If villagers are interested in participating in the study, the time of day for the visits 
during the study will be agreed upon.  A person in the village will be identified during the 
discussions with village elders and villagers who will serve as the local focal point for the study 
within the village. 
6.1.3.2 Preliminary survey  
During the preliminary survey, males and non-pregnant (based on 'self-assessment') females in 
each community meeting the age inclusion criterion will be invited for a Loa microfilarial load 
assessment.  
Prior to the initiation of each volunteer's screening for Loa loa, the informed consent information 
for this part of the study will be given to the potential volunteers to read or will be read to them 
(as per their preference), questions answered and informed consent obtained via signature or 
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thumb print.  The common language used in this part of Cameroon is French.  Both genders are 
legally adults in Cameroon at 18.   
Each subject who gives informed consent will be given a subject number.  In case report forms, 
the subjects name will not be used, only subject number and initials. 
During the preliminary survey, subjects will: 
• Have a blood sample (50 µl via finger prick and capillary tube) taken for parasitological 
examination.  The blood sample will be labeled with the date and time of collection and 
subject number. 
Given the diurnal variation in blood microfilaria levels (Kamgno & Boussinesq, 2002, Figure 1), 
blood samples for screening (as well as baseline and for efficacy follow up evaluations) will be 
obtained between 11:00 and 15:00 o'clock.  All possible efforts will be made so that for each 
village the examination time will be about the same throughout the study. 
The date and time of day of the collection of a blood sample for each subject will be recorded. 
During the preliminary survey, a general medical consultation will be offered to those who have 
medical complaints (including villagers who want medical consultation but do not want to 
participate in the preliminary survey for LLM) and some drugs will be available to treat subjects 
with any ailment that is amenable to treatment in the village. 
Subjects who are not eligible for the subsequent part of the study will be given the explanation 
this. 
6.1.3.3 Definitive subject qualification for the study  
All subjects who have >15 000 L. loa  microfilaria/ml based on the preliminary survey will be 
included in the definitive subject identification activities via evaluation for exclusion criteria if 
they consent to it.  Prior to this section of the study, the informed consent information for the 
remainder of the study will be given to these subjects to read or will be read to them (as per 
their preference) and the study will be discussed with them, questions answered and informed 
consent obtained via signature or thumb print.   
For the definitive subject qualification, subjects will undergo 
• A clinical examination to assess presence of any serious underlying medical condition, 
clinical signs and symptoms of intestinal helminths, clinically evident liver disease, kidney 
disease or anaemia.  In subjects with clinical signs and symptoms of intestinal helminths 
(abdominal pain, diarrhoe, vomiting, anaemia) a stool examination for helminths will be 
conducted) 
• Questioning about treatment with benzimidazole during the past 12 months 
• Questioning about allergy to benzimidazoles 
• Questioning for past or current history of neurological or neuropsychiatric disorders 
• Pregnancy test on a urine sample (β-HCG) (all women of childbearing potential) 
• Venous blood sampling (4 ml) for transaminase activity (Alanine aminotransferase (ALT, 
SGPT), aspartate aminotransferase (AST, SGOT), creatinine levels, haemoglobin levels and 
complete blood count (CBC). 
6.1.3.4 Definitive subject selection  
Whether or not a subject's microfilaria count drops by ≥ 50% may depend on the initial 
microfilaria burden.  Of particular interest for this study are those, relatively rare, subjects with 
pretreatment LLM of >30000 mf/ml since those are the ones most likely to experience signs and 
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symptoms of loiasis and potential long term sequelae of loiasis and are also those at highest 
risk for SAEs upon ivermectin treatment (see Table 1).   
Thus, if more than 60 subjects have qualified for participation in the study based on evaluation 
of inclusion and exclusion criteria, the 60 subjects with the highest microfilaria counts will be 
selected for the study (see section  6.2.4.2 and section  10). 
Subjects who are not eligible or are not being selected for inclusion in the study will be given an 
explanation for the reason of their exclusion and referred to medical attention if indicated. 
6.1.3.5 Baseline LLM in subjects selected for study participation 
On the day of the first treatment, subjects selected for study participation will have a blood 
sample (50 µl via finger prick and capillary tube) taken for parasitological examination for 
baseline microfilaria counts (Loa loa and other parasites in the blood, if applicable, e.g. 
Mansonella perstans).  For subjects in which the preliminary survey indicated LLM above 30000 
mf/ml, the blood sample will be distributed over two slides for accurate quantitation of baseline 
LLM. The blood samples will be labeled with the date and time of collection and subject number. 
6.1.3.6 Subject information on screening results 
Subjects will be informed individually verbally of the results of the examinations performed on 
them and also provided cards with their name (and photo unless they do not want one) and the 
results of all tests performed as well as all treatments administered based on the results of the 
examinations performed during the screening.   
For subjects who participate in the study, these cards will be updated with any results relevant 
to their medical history that may be obtained during the examinations performed during the 
course of the study. 
6.1.4 Subject identification and screening log  
A record of all subjects screened will be maintained (screening log).  The screening log will 
contain the following information: 
• Date of screening 
• Subject name 
• Subject initials  
• Subject number  
• Village 
• Date of birth (or age if date of birth unknown) 
• Gender 
• Passed or failed screen 
• Reason for screen failure (if applicable) 
6.1.5 Screen failures 
Subjects who sign or thumbprint an informed consent form but are found during screening not to 
qualify for the study are regarded as screen failures and the reason for the screen failure will be 
recorded in the screening log.   
Subjects who do not qualify for the study or were not selected despite fulfilling all inclusion and 
no exclusion criterion, will be provided individually, verbally an explanation for the reason of 
their exclusion from the study.  
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If subjects who fail screening were discovered during the preliminary survey to have L.loa (or 
Mansonella perstans another parasite in the blood), they will be informed about this.  There is 
no safe and effective treatment for either L. loa infection or  Mansonella perstans.   
If subjects were discovered during the screening examination to have a disease that needs 
treatment beyond the capacity of the study team, they will be informed about their disease and 
referred to medical attention for consultation and treatment. A district medical officer is part of 
the study team.   
6.1.6 Subject withdrawal 
6.1.6.1 Withdrawal from the study 
Subjects will be told during the informed consent process that they can withdraw from study 
treatment or from the whole study at any time.   
Subjects who want to withdraw from the whole study at any time after the first treatment will be 
asked to undergo one last clinical examination and examination for adverse events.   
The investigator will withdraw any subject from the study at any time if he feels that that is in the 
best interest of the subject. 
6.1.6.2 Withdrawal from study treatment 
Subjects will be withdrawn from further treatments if they become pregnant or develop another 
exclusion criterion with the exception of intestinal helminths, experience a serious adverse 
event, or develop any other medical conditions that in the investigator's opinion should result in 
study drug withdrawal. 
Subjects who are diagnosed with intestinal helminths during the study will be withdrawn only 
from the next study treatment and receive 800 mg of albendazole. For subsequent scheduled 
treatments, these subjects will again receive the blinded treatment they were randomized to.   
Subjects who are withdrawn from study treatment but not the study will continue to be followed 
up until the last scheduled efficacy follow up. 
6.1.6.3 Reasons for withdrawal 
For a mass treatment with albendazole to reliably reduce LLM to levels that do not expose Loa 
loa infected subjects to risk of severe and/or adverse events upon mass ivermectin treatment for 
onchocerciasis or LF control, compliance of all individuals in a community is key.  Compliance 
with a multiple dose treatment with doses administered in several month intervals is a major 
challenge for mass treatments.  To enable appropriate information, education and motivation for 
compliance to be implemented in the mass treatment schemes it is important to understand 
reasons for non-compliance.   
To obtain compliance related data that can be used to appropriately design further evaluation of 
multiple dose albendazole regimen(s) for mass treatment not only in terms of efficacy and 
safety, but also in terms of field implementation, subjects who withdraw their consent to further 
study treatment or further participation in the study, and subjects who do no participate in all 
scheduled treatment days, will be asked to provide the reasons.  During the informed consent 
process it will be explained to subjects not only that they have the right to withdraw from the 
study at any time, but also that they have no obligation to answer the question for the reason of 
their withdrawal.   
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6.1.7 Description of methods used during screening and baseline data acquisition 
6.1.7.1 Parasitological examination 
The method of parasitological examination at screening and baseline data acquisition as well as 
at each efficacy follow up visit (2, 4, 6, 8, 10, 14, 18 months post first treatment) will be the 
calibrated blood smear (CBS).  This method is to date the best quantitative examination for 
LLM. It has been used in all trials related to loiasis, and for the basis/validation for RAPLOA, the 
method now used by the onchocerciasis control programs to identify areas with high prevalence 
of loiasis.   
This examination will be done by finger prick after a careful cleaning of the finger. The blood will 
be collected with a 50µl non-heparinized capillary tube, the 50 µl spread on a labeled slide, 
dried and Giemsa stained and dried at ambient temperature.  All L. loa and Mansonella 
perstans microfilariae on the slide will be counted at a magnification of 100.  L. loa and 
Mansonella perstans microfilariae are distinguished primarily based on size, since M. perstans 
microfilaria are approximately half the size of Loa loa microfilaria.  When necessary correct 
identification will be verified via the membrane surrounding Loa loa microfilaria which becomes 
visible at higher magnification (400 or 1000).  
All slides will be read by the same technician throughout the study with subject number, data 
and time of sample (but not treatment assignment) known to the technician and again at the end 
of the study with the technician blinded to subject number, date and time of sample.  The result 
of the blinded reading will be used for data analysis.  If the counts obtained for a specific sample 
during and at the end of the study differ by >10%, the slide will be read again.  The mean of the 
two blinded readings performed after the end of the study will be used for the data analysis.  
6.1.7.2 Clinical examination 
The clinical examination (CE) to be conducted prior to each treatment (see section  6.2.1) will 
include medical history pertinent to inclusion/exclusion criteria, the examination of the 
conjunctivae, temperature, blood pressure, auscultation of the heart and lung, and palpation of 
the abdomen. 
6.1.7.3 Laboratory evaluations 
Alanine aminotransferase activity, aspartate aminotransferase activity, creatinine levels and 
hemoglobin levels will be determined using a Reflotron.CBC will be obtained automatically using 
am ABX PENTRA 120.  
Pregnancy test will be done using urine analyzed with HCG urine/serum test from AMS France. 
6.2 SUBJECT TREATMENT 
6.2.1 Study drugs and treatment regimen 
Albendazole 200 mg tablets and matching placebo will be provided by GSK.  4 tablets of active 
or placebo will be administered to each subject.   
At 0, 2, 4, 6, 8 and 10 months, each subject will be administered after a standard fatty meal (one 
wheat fritter of 45-50 g filled with approximately 25 g of butter, commonly eaten by the local 
population and provided to participants as part of this study) orally either 800 mg of Albendazole 
or placebo, depending on the treatment group they have been randomized to. 
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Time Group 1  Group 2  Group 3  
Month 0 Placebo Albendazole 800 mg Albendazole 800 mg 
Month 2 Placebo Albendazole 800 mg Albendazole 800 mg 
Month 4 Placebo Placebo Albendazole 800 mg 
Month 6 Placebo Placebo Albendazole 800 mg 
Month 8 Placebo Placebo Albendazole 800 mg 
Month 10 Placebo Placebo Albendazole 800 mg 
 
6.2.2 Choice of control treatment 
Three of the studies conducted to date evaluated the effect of different dosing regimens of 
albendazole on loiasis microfilaremia in comparison to no treatment.   
The data from the subject groups who received no treatment show that Loa loa microfilaremia 
can vary significantly over time without any treatment.  Klion et al. (1993) reported that 
geometric mean microfilaria levels in the placebo group varied between 32% and 192% of 
pretreatment levels over the 6 months follow up time without a consistent trend and including a 
drop from 192% to 84% of pretreatment values within a period of 3 months.  The data from the 
study of Tsague-Dongmo et al (2002) showed among subjects with pretreatment levels >8000 
mf/ml variations of microfilaria levels of between 73% and 114% of pretreatment values over a 
period of 9 months, including a drop by 30% over a period of 30 days (see Table 2).   
The inclusion of a placebo group is consequently required to assess whether any of the two 
albendazole treatment regimens is effective, i.e. to see whether any changes in the treatment 
arms receiving albendazole are actually albendazole-associated and/or larger than the natural 
longitudinal variation of microfilaria counts as observed in the placebo group.  This in turn is the 
prerequisite for planning further steps to qualify a multiple dose albendazole regimen for 
reduction of LLM on a community treatment basis. 
6.2.3 Determination of compliance 
All drugs will be administered to the subjects by study personnel.  Thus, compliance will be 
directly observed. 
Date and time study drug was taken will be recorded. 
6.2.4 Measures to minimize bias 
6.2.4.1 Blinding during treatment and unblinding in case of emergencies 
Treatment will be double-blinded (matching albendazole and placebo tablets) and subjects will 
be randomized to reduce bias in data collection and interpretation. 
Given the safety record of albendazole and the fact that the product label for indications that 
require 400 mg bid dosing of albendazole for up to 30 days, recommends symptomatic 
treatment (gastric lavage, activated charcoal) and general supportive measures in case of 
overdose, it unlikely that unblinding the treatment of a subject during the trial will be necessary. 
If against all expectations, unblinding will be necessary, the pharmacist who prepared the study 
medication (see section  6.2.5), and is not otherwise associated with the study, will provide the 
treatment assignments to the investigator.  This person will also provide the randomization 
codes to the GSK Safety / Case Management Group for unblinded reporting of SAEs to the 
regulatory authorities: 
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GSK Safety Group  Contact Person Helen Goumeas 
  Fax number: +44 (0)208 4239534 
 Phone number:  +44 (0)20 8966 2256 
 e-mail: Helen.Q.Goumeas@gsk.com 
The sponsor will be informed within 3 days if the treatment of a subject was unblinded, the 
reason for the unblinding and the actions taken after unblinding. 
6.2.4.2 Randomization 
Whether or not a subject's microfilaria count drops by ≥ 50% of pretreatment values may 
depend on the initial microfilaria burden.   
Of particular interest for this study are those, albeit rare, subjects with pretreatment LLM of 
>30000.  Thus, if more than 60 subjects have qualified for participation in the study, the 60 
subjects with the highest microfilaria counts will be selected for the study and randomized taking 
into account the requirement for similar distribution of pre-treatment LLM in the three treatment 
arms.  At least 5 of the 20 subjects enrolled in each treatment arm should have a screening LLM 
of >30000 mf/ml. 
To take into account that the drop in LLM may be dependent on the pre-treatment LLM, 
randomization will be by strata defined by the pre-treatment microfilaremia level obtained at 
screening, see section  6.1.3.2.  The microfilaremia strata will be: 
• 15 001 to 30 000 mf/ml  
• 30 001 to 50 000 mf/ml  
• ≥ 50 001 mf/ml. 
A person not involved in the treatment or follow up of the subjects will generate three 
randomization lists i.e. pairs of randomization number and treatment assignment, one for each 
of the three strata.   
Given the low prevalence of subjects with LLM ≥30001 and even more so ≥50001, the number 
of subjects in these microfilaremia strata is likely to be small.  To ensure equal distribution of the 
subjects in each microfilaremia stratum across the three treatment arms, randomization will be 
performed in blocks of three, i.e. among three success randomization numbers, one will be 
assigned to placebo treatment, one to 2 doses of albendazole and one to 6 doses of 
albendazole.   
Subjects who have qualified and have been selected for the study will be assigned the next 
unassigned number on the randomization list for their stratum in the order of their subject 
number. 
6.2.5 Study drug preparation 
Based on the randomization lists with their pairs of randomization numbers and treatment 
assignments for each microfilaria stratum, the pharmacist will prepare prior to each treatment 
round treatment packages labeled with the randomization number and strata.   
6.2.6 Study drug administration and recording 
For each subject who received treatment, the following information will be immediately recorded 
after each treatment in the 'site treatment records': 
• subject number 
• subject initials  
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• randomization number on the drug package from which his/her treatment was taken  
• initials of the person who administered the drug 
• date and time of administration 
After each visit that involves treatment, the investigator will provide the site treatment records to 
the pharmacist who will use them to fill in the drug accountability forms and then provide the site 
treatment records back to the investigator. 
If a treatment package was not used because of subject withdrawal, the treatment package will 
be returned to the pharmacists. 
6.2.7 Accountability for study drug  
The PI is responsible for ensuring appropriate accounting for all unused study drugs and all 
used and empty study drug containers.  
Drug accountability records will be maintained by the unblinded pharmacist who prepares the 
treatment packages based on the randomization lists and the records provided by the 
investigator (see section  6.2.6).   
For both albendazole and placebo the following information needs to be recorded: 
• Drug received: type of drug (albendazole or placebo), lot number, quantity and date of 
receipt,  
• Drug administered: For each administration: date, type (albendazole or placebo) quantity, 
subject randomization number, subject initials, subject number, initials of person who 
prepared the drug, initials of person who administered the drug (to be provided to the 
unblinded pharmacist by the investigator or his designee). 
At the termination of the study, a final drug accountability review and reconciliation will be 
completed, any discrepancies will be investigated, and their resolution will be documented.  All 
unused study drugs will be taken care off as per instructions from Glaxo-SmithKline to the 
Principal Investigator with copy to the TDR project manager.   
6.2.8 Prohibited and permitted prior treatments 
Benzimidazole treatment within the previous 12 months is an exclusion criterion.   
All other medication, whether prescription, over-the-counter or herbal preparations prior to 
treatment within this study is permitted.   
6.2.9 Prohibited concomitant treatment 
Subjects will be advised not to take anti-filarial treatment (Mectizan (ivermectin) or 
Diethylcarbamazine) or any antihelminthic treatment during the study (including albendazole 
outside the study treatment).  Since the diseases for which ivermectin and DEC are indicated 
are not prevalent in the study area, it is unlikely that subjects would be prescribed these drugs.   
The fact that each follow up is associated with a general medical examination and treatment of 
common illnesses further reduces the probability of subjects pursuing and getting access to 
these drugs. 
There are no restrictions on other concomitant medication. 
At each visit, subjects will be asked about the medication they have taken since the last study 
drug administration and this will be recorded in the source records and case report form, if 
available with indication, doses and dates of administration.  
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7 ASSESSMENT OF EFFICACY 
7.1 Efficacy Variables 
The efficacy evaluation will be based on the examination of the slides generated from the 
calibrated blood smears for the determination of the L. loa microfilaria counts.   
7.1.1 Primary 
The primary efficacy variable is the proportion of subjects in each treatment group whose 
microfilaria count has been sustainably reduced by 50% from the baseline value at any time 
point after the first dose.  A sustainable reduction by 50% is defined as a reduction to 50% of 
baseline LLM for at least 4 months. 
7.1.2 Secondary 
Secondary efficacy variables are: 
• The proportion of subjects whose microfilaria counts have been reduced sustainably to 
<8100 mf/ml after the first dose  
• by treatment group and microfilaria strata 
• by treatment group stratified by gender 
• by treatment group stratified by gender and initial microfilaria count 
• The percent reduction in microfilaria counts at each time point quantitated via the range, 
William geometric mean and median  
• by treatment group across all patients  
• by treatment group stratified by initial microfilaria count 
• by treatment group stratified by gender 
• by treatment group stratified by gender and initial microfilaria count 
• The evolution of Loa parasitemia with time in each treatment group analysed via General 
Linear Model 
7.2 Method and timing of measurement of efficacy parameter 
The method of parasitological examination at screening and at each efficacy follow up will be 
the calibrated blood smear (CBS). This examination will be done by finger prick after a careful 
cleaning of the finger. The blood will be collected with a 50µl non-heparinized capillary tube, 
spread on a labeled slide, dried and stained. More details are provided in section  6.1.7.1. 
Blood samples for baseline LLM as well as for all efficacy follow up evaluations (at M2, M4, M6, 
M8, and M10, and at M 14 and M18) will be obtained between 11:00 and 15:00 o'clock.  
The date and time of day of the collection of a blood sample will be recorded and visits will be 
planned in a way that each village is visited at the same time of day throughout the study. 
In a previous study determining L. loa periodicity in subjects who had developed adverse effects 
after treatment with ivermectin and in control subjects (Kamgno et al., 2004, Figure 1), the Loa 
parasitemia was relatively stable (variation ≤20%) between 11:00 and 15:00.  
Collection of samples between 11:00 and 15:00 in combination with scheduling visits to a 
particular village for the same time of day will ensure that the results will be comparable 
between and within the groups and that diurnal variation will not compromise the efficacy 
analysis.   
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8 ASSESSMENT OF SAFETY 
8.1 Safety Variables 
All safety variables will be derived from the adverse events reported by the subjects and/or 
observed during the clinical evaluations. 
The frequency of treatment emergent adverse events will be compared by type of adverse 
event, severity and relationship to study drug between treatment groups. 
Serious adverse events will be tabulated by relationship to study drug and treatment group. 
Narratives will be provided for each event. 
8.2 Methods and timing for assessing adverse events 
Follow up for adverse events will be conducted on the day of treatment, at day 3 and day 7 after 
each treatment as well as at the next treatment or efficacy follow up visit (M2, M4, M6, M8, and 
M10, and at M 14 and M18.  Adverse events will also be determined through the clinical 
examination conducted prior to each treatment, and if clinically indicated through laboratory 
evaluations.  If clinically indicated or indicated based on the report of adverse event(s) by the 
subject, a complete blood count and laboratory evaluations will be performed as appropriate. 
Any study related adverse events will be treated either in the village by the study team or in a 
hospital or treatment center to which the subject will be transferred if the adverse event cannot 
be treated in the village by the study team. A district medical officer is part of the study team. 
If any non study related adverse events are diagnosed during the clinical examination the 
subjects will either be treated by the study team if this is within the capacity of the study team or 
they will be referred to a hospital or treatment center. 
In both cases the investigator will discuss with the subjects their continued participation in the 
study.  If this is not consistent with the well being of the subject, the investigator will withdraw 
the subject from further treatment or from the whole study. 
For each adverse event the following information will be recorded: 
• Subject number, subject initials, randomization number 
• Type of adverse event 
• Start date and time 
• End date and time 
• Severity (see section  8.4) 
• Whether the adverse event is due to a pre-existing condition (ie, an acute condition present 
at the start of the study or history of a chronic condition), and was present prior to study start 
or study treatment 
• Relationship to study treatment (see section  8.5). 
• Action taken;  
• Outcome.   
All adverse events will be followed up to resolution or until a study-unrelated cause has been 
established. 
The methods for clinical examination and laboratory tests for ALT, AST, creatinine and 
haemoglobin and pregnancy are described in section  6.1.7.2 and  6.1.7.3.   
Other laboratory tests will be conducted if clinically indicated.   
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8.3 Adverse event definitions 
8.3.1 Adverse event 
An adverse event is defined as any untoward, undesired, unplanned clinical event in the form 
of signs, symptoms, disease, or laboratory or physiological observations occurring in a human 
being participating in a clinical study with a study drug, regardless of causal relationship.  This 
includes the following: 
• Any clinically significant worsening of a preexisting condition. 
• Any recurrence of a preexisting condition. 
• An AE occurring from overdose of a study drug whether accidental or intentional (ie, a 
dose higher than that prescribed by a health care professional for clinical reasons). 
• An AE occurring from abuse of a study drug (ie, use for nonclinical reasons). 
• An AE that has been associated with the discontinuation of the use of a study drug. 
Note:  A procedure is not an AE, but the reason for a procedure may be an AE. 
8.3.2 Treatment emergent adverse events 
Treatment emergent adverse events are adverse events that occur after administration of the 
study drug. 
8.3.3 Serious adverse event 
A serious adverse event (SAE) is any AE occurring at any dose that meets 1 or more of the 
following criteria: 
• Results in death 
• Is life threatening  
The term 'life-threatening' refers to an event in which the subject was at risk of death at 
the time of the event. It does not refer to an event, which hypothetically might have 
caused death, if it were more severe. 
• Requires inpatient hospitalization or prolongation of an existing hospitalization  
In general, hospitalization signifies that the subject has been detained (usually involving 
at least one overnight stay) at the hospital or emergency ward for observation and/or 
treatment that would not have been appropriate in the physician's office or out-patient 
setting.  Complications that occur during hospitalization are AEs.  If a complication 
prolongs hospitalization or fulfills any other serious criteria, the event is 'serious'.  When 
in doubt as to whether 'hospitalization' occurred or was necessary, the AE should be 
considered 'serious'.  Hospitalisation for elective treatment of a pre-existing condition 
that did not worsen from baseline is not considered an AE. 
• Results in a disability / incapacity  
The term disability means a substantial disruption of a person's ability to conduct normal 
life functions.  This definition is not intended to include experiences of relatively minor 
medical significance such as uncomplicated headache, nausea, vomiting, diarrhoea, 
influenza and accidental trauma (e.g. sprained ankle) which may interfere or prevent 
everyday life functions but do not constitute a substantial disruption. 
• Results in a congenital anomaly or birth defect 
If there is any doubt if an event is an AE or SAE, the event is to be classified as an SAE. 
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8.4 Assessment of severity of adverse events 
The severity of adverse events will be graded as  
Mild: An event that is easily tolerated by the subject, causing minimal 
discomfort and not interfering with everyday activities 
Moderate: An event that is sufficiently discomforting to interfere with everyday 
activities 
Severe: An event that prevents normal everyday activities 
Not applicable: Events where intensity is meaningless or impossible to determine (i.e. 
blindness and coma).  
8.5 Assessment of relationship of adverse event to study drug 
When assessing the relationship between administration of a study drug and an AE, the 
following should be considered: 
• Temporal relationship between administration of the study drug and the AE 
• Biological plausibility of relationship (i.e. consistent with the pharmacological action of the 
drug) 
• Subject’s underlying clinical state (concurrent illness, relevant medical history) or 
concomitant agents and/or therapies 
• When applicable, whether the AE decreases in severity on discontinuation of the study drug 
(dechallenge) 
• When applicable, whether the AE reappears or increases in severity on repeat exposure to 
the study drug (rechallenge, Note: a subject should not be re-administered a drug if there is 
a suspicion that the drug may have caused an adverse event and there is no reason to 
believe that the benefit for the patient from the rechallenge outweighs the potential risk of 
the AE if it is indeed causally related to the drug administration) 
 
Reasonable 
possibility of 
relationship 
to study drug  
Criteria 
The adverse event  
Yes Has a reasonable temporal association with study drug administration 
And/or follows a known response pattern to the study drug 
And could or could not have been produced by other factors such as the 
subject's clinical state, therapeutic intervention or concomitant therapy 
No 
 
The event was most probably produced by other factors such as the subject's 
clinical state, therapeutic intervention or concomitant therapy 
OR 
The event is clearly related to other factors such as the subject's clinical status 
therapeutic intervention or concomitant therapy 
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8.6 Reporting of serious adverse events and pregnancies to GSK, TDR and National 
regulatory authorities 
All AEs and SAEs will be recorded on source documents and recorded on CRFs.   
8.6.1 Serious adverse events 
All SAEs will be reported by the PI on the SAE reporting forms to GSK, and to the National 
regulatory authorities as per their requirements within 24 hours of the investigator learning about 
them. The investigator has to provide follow-up information concerning the outcome 
independent on whether the subject was discontinued from the study due to the pregnancy or 
other reasons.  
The SAE reporting forms in the Attachment include the information to be provided.  The filled 
out forms will be faxed to: 
GSK Global Clinical Safety & Pharmacovigilance (GCSP):  FAX  +44-208-4239534 
 PHONE:  +44-208-4223434 
8.6.2 Pregnancies 
All pregnancies that occur during the study will be reported to GSK within 2 weeks of the 
investigator learning about them on the form provided in the Attachments. 
When possible, all reports of pregnancy must be followed up for information about the course of 
the pregnancy and delivery, as well as the condition of the newborn and the data reported to 
GSK on the form provided in the Attachments.  The filled out forms will be faxed to the same fax 
number as the SAE information. 
9 DATA ANALYSIS 
9.1 Sample Size Justification  
A positive response in a subject is defined as a drop in LLM from baseline values by ≥50% 
lasting at least 4 months. Assuming that in the population less than 1/106 subjects will have a 
positive response if randomized to the placebo group and at least 50% of the subjects will have 
a positive response if randomized to the 6 dose albendazole treatment regimen, a sample size 
of 16 subjects in each treatment arm will provide at least 90% power to detect statistically 
significant (two-sided α=0.025) differences between the placebo group and the 6 dose 
albendazole treatment group.  The same assumptions were made for the 2 dose albendazole 
treatment regimen so that the same power and sample size considerations apply to the 
comparison between placebo and the 2 dose albendazole treatment. An alpha value of 0.025 
was chosen since two comparisons (placebo vs. 2 doses of albendazole, placebo vs. 6 doses of 
albendazole) will be performed.  Based on prior experience, a drop out rate of approximately 
20% is expected, resulting in a sample size of 20 subjects for each of the three treatment arms.  
9.2 Statistical Methods 
9.2.1 Efficacy analysis 
Proportions of patients with a sustained reduction of LLM from baseline by ≥50% between each 
active treatment group and the placebo group will be compared by the Chi square test. 
Loa parasitaemia will be compared at each point between groups using non-parametric test due 
to the non normal distribution of the Loa microfilaremia. The General Linear Model (GLM) will 
also be used for the comparison of the evolution of Loa parasitemia in different groups. 
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9.2.2 Safety analysis 
Calculation of the proportion of subjects with AEs and SAE by treatment group, type of AE, 
gender, severity and relationship to study drug (see section  8.1). 
9.2.3 Analysis populations  
Two populations will be analyzed for efficacy: 
Per protocol population: includes all subjects who were received the full treatment course they 
were randomized to and have a final efficacy assessment. . 
Intent to treat population:  includes all subjects who received at least one dose of study drug 
and have a final efficacy assessment. 
All subjects who received at least one dose of study drug will be included in the safety analysis. 
9.2.4 Interim Analysis  
No interim analysis is planned. 
9.2.5 Reasons for discontinuation of treatment/study 
For subjects who have provided reasons for discontinuation of participation in study treatments 
or the whole study or for their not attending all scheduled treatment days, the reasons will be 
categorized into four groups:  
• reasons related to drug administration,  
• reasons related to study drug procedures, but not drug administration,  
• other reasons, 
• no reason provided 
and the proportion of subjects in each category will be calculated by number of treatments prior 
to withdrawal. 
This analysis can serve as input into the design of a follow up study (if the present study 
provides proof of concept) which needs to include addressing how a multiple dose albendazole 
regimen can be implemented for community treatment in a way that maximizes compliance.  
Compliance will be critical to achieving reliable reduction of Loa loa microfilaremia below the risk 
level in the total population to be treated subsequently with ivermectin.  
10 PROBLEMS ANTICIPATED 
Problems anticipated and contingency plans:  
• Prevalence of L.loa in the study area and/or percentage of subjects eligible and willing to 
participate in the study too low to recruit the target number of subjects.  This will necessitate 
screening a larger number of subjects to achieve the necessary number of subjects. 
• The number of subjects with high microfilaria levels (>30000) tends to be low, even in areas 
with high prevalence of Loa loa.  Since subjects with this level of Loa loa microfilaraemia are 
those most likely to experience signs and symptoms and potential long term sequelae of 
loiasis and are at high risk for SAE in case of ivermectin treatment, they are of particular 
interest in this study.  If after final subject qualification the number of subjects with >30000 
mf/ml is lower than 15, measures for recruitment of subjects with high microfilaria levels will 
be discussed with the sponsor. 
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11 ETHICS 
11.1 Informed consent 
The method for obtaining informed consent is described in section  6.1.3.2.  The informed 
consent information is provided in the Attachment.  
11.2 Gender related issues 
Ideally, 50% of the subjects in each microfilaria strata would be women.  However, because of 
(1) pregnancy being an exclusion criterion and (2) prevalence and intensity of infection tending 
to be lower in females than males, it is unlikely that this will be achieved.  There is currently no 
reason to suspect that the host gender affects the response of the parasite to albendazole.  
11.3 Potential risks to subjects 
No experimental procedure is being used in this study.  The protocol procedures the subjects 
will undergo include a finger prick (to obtain samples for the parasitological examinations at 
screening, prior to each treatment and at the additional efficacy follow up visits) and a venous 
blood sample (4ml ) for determination of ALT, AST, creatinine and haemoglobin levels and a 
CBC at the screening visit (see section  6.1.3).  The risks associated with these procedures are 
minimal. 
Subjects will be treated with albendazole which is being used in Cameroon and other countries 
for treatment of intestinal worms and has been proven to be safe for mass treatment of 
lymphatic filariasis without medical supervision (Horton et al., 2000; Ismail et al., 2001). During 
the previous trials with albendazole in subjects with loiasis, there were either no clinical adverse 
effects and no observed hepatotoxicity, renal toxicity, or hematologic abnormalities attributable 
to the drug (Klion et al., 1993) or adverse events were not severe, transient and/or observed 
with similar frequency in the placebo group (see section  3).   
11.4 Potential benefits to subjects 
Subjects who participate in the preliminary survey as well as in final subject selection will benefit 
from having their health status evaluated and either treated immediately, or being referred to a 
hospital/treatment center for treatment of illnesses that go beyond the treatment capability of the 
study team in the village. 
Any subject who qualifies for and participates in the study will benefit from having clinical 
examinations and treatment of minor illnesses as part of the study, or referral to the next health 
center for illnesses outside the scope of village-based treatment during this study every two 
months.   
The prevalence of intestinal helminths, in particular hookworm (Ratard et al, 1992), in the study 
area is low with less than 15% of adults estimated to be infected.  Thus, only the rare subject 
who participates in the study and has intestinal helminths not accompanied by signs and 
symptoms (e.g. diarrhoea, abdominal pain, vomiting) and is randomized to one of the two 
albendazole treatment groups could benefit from the effect of albendazole on their intestinal 
helminths.  Given that albendazole is a very safe treatment, this potential benefit will be 
extended to subjects who received only placebo during the study by offering them albendazole 
treatment after completion of the study and unblinding.   
If one or both of the albendazole treatment regimens result in reduction of L.loa microfilaremia, 
those subjects in which this reduction occurs will benefit from this.   
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Since this is a small proof-of-concept study, expansion of a treatment regimen for which the 
benefit has not yet been definitively established to all study participants or the community from 
which they are coming is premature. 
11.5 Potential benefits to communities 
Communities with loiasis would benefit from the development of a safe and effective treatment 
reducing LLM, because there is currently no safe treatment for to reduce LLM and physicians 
are thus not able to offer treatment to Loa loa infected subjects who asked for that type of 
treatment.   
Among communities with loiasis, those co-endemic for onchocerciasis and/or lymphatic filariasis 
would benefit additionally from a mass treatment suitable Loa loa treatment through the reduced 
risk of SAEs during CDTI and/or implementation of lymphatic filariasis control. 
11.6 Inclusion of a placebo arm 
As outlined in section  3, inclusion of a placebo group is necessary to be able to assess whether 
any reduction of microfilaremia counts in either of the two albendazole treatment arms is 
statistically significantly associated with the use of albendazole and thus likely to reflect more 
than the natural longitudinal variation of LLM as seen in the placebo group. 
11.7 Data safety monitoring 
Given albendazole's excellent safety record in the treatment of intestinal helminths and in 
lymphatic filariasis control programs, a data safety monitoring board is not required. 
11.8 Information of the communities of the study results 
Once the final data from the study are available and have been discussed with the stake 
holders, each community will be visited to inform them about the results and what will be done 
in consequence of the results obtained. 
11.9 Subject Compensation 
Subjects included in this trial will be compensated for any expenses incurred during the 
transport to the study site but will not have direct financial compensation for study participation.  
Information on indirect compensation via the treatment of minor complaints detected during the 
clinical examinations is provided in section  11.4. 
11.10 Insurance 
A clinical trial insurance will be taken out through TDR. 
12 OBLIGATIONS OF THE INVESTIGATOR 
The principal investigator will ensure that the study will be conducted in accordance with the 
ethical principles that have their origin in the Declaration of Helsinki (as amended, October 
2000) and that are consistent with good clinical practice (GCP) and the Standard Operating 
Procedures for Clinical Investigators (TDR/TDP/SOP/99.1). 
12.1 Ethics Committee Approval 
The protocol and the informed consent form will be approved by the Ethics Committee of the 
Cameroon Health Service and the WHO prior to initiation of the study.  
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12.2 Pre study Documentation 
The principal investigator will provide the sponsor with the following documents: 
• A copy of the National Ethics Committee (NEC) approval letter for the protocol and 
informed consent. Any changes in this study or unanticipated problems involving risks to 
the subjects will be reported promptly to the NEC and the TDR Product Manager.   
• Current signed and dated curricula vitae for the investigators 
• Copy of the approved informed consent documents to be used. 
• Copy of the protocol sign-off page signed by the investigators. 
Subject screening will not be initiated until clearance has been received from the National Ethics 
Committee and the WHO Ethics Review Committee. 
12.3 Study management 
The principal investigator is responsible for assigning the responsibilities to each study team 
member and to ensure that they fulfill their responsibilities. 
The study team will consist of: 
• One medical doctor who will assist the principal investigator in examining the patients. 
• Two Laboratory technicians who will be responsible for collecting blood samples for CBS 
and laboratory evaluations. 
• One nurse who will measure blood pressure and body temperature as needed. 
• One secretary who will register patients during the preliminary survey, and who will also help 
in registering data. 
• One local person in each village who will assist the principal investigator in the sensitization 
of patients and help participants to liaise with the PI during the course of the study between 
visits to the villages. 
• One district medical officer. 
12.4 Informed Consent 
Informed consent will be obtained prior to any study related procedures (see attached).  
12.5 Serious Adverse Event Reporting 
The principal investigator agrees to report all SAEs to GSK and the National Cameroonian 
authority, as per their requirements and described in section  8.6.  
GSK Global Clinical Safety & Pharmacovigilance (GCSP):  FAX  +44-208-4239534 
 PHONE:  +44-208-4223434 
The principal investigator is responsible for ensuring that any sub-investigator promptly brings 
SAEs to the attention of the investigator.  
12.6 Source Records 
The principal investigator is responsible for recording of all relevant data in the source records 
and their correct transcription to the CRF. 
The principal investigator agrees that qualified representatives of the sponsor and the national 
authority have the right, both during and after this study, to direct access to the source 
documents.  
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12.7 Protocol Amendment 
Once the study has started, the investigator will adhere to the protocol and ensure that it is 
strictly followed. Deviations to protocol procedure(s) that involve the subjects will not be made 
without the agreement of the sponsor except when necessary to avoid immediate danger to a 
trial subject.  
Proposed changes will be discussed with the TDR Product Manager. If the TDR Product 
Manager agrees to the changes, they will be outlined as a protocol amendment along the lines 
indicated in the TDR SOP for Clinical Investigators. The document will be signed by the 
investigator and TDR Product Manager and appended to the original protocol.  
Any such modification of the protocol that has an impact on the risk and benefits of the study 
participants will require a submission to the National EC and the WHO ERC prior to 
implementation.  
In the case of minor modifications that do not have impact on the risk-benefit of the subjects 
during participation in the trial, or which only impact on administrative activities, the modification 
will be considered a simple notification that does not require Ethics Committee approval. 
12.8 Quality Assurance 
The principal investigator is responsible for ensuring that all members of the study team are 
trained on the requirements for conducting the study according to Good Clinical Practice and 
the applicable regulatory requirements.   
The investigator will accordingly ensure that  
• the data in the source records are accurate, complete and legible,  
• transcribed accurately to the Case Report Forms 
• entered accurately into the data base and analysed as planned in the protocol. 
Adherence to GCP, consistency of the data in the source records with those on the CRF and 
drug accountability will be monitored by a TDR clinical monitor. 
12.9 Interim Report 
11 months after the initiation of the study the investigator will provide an interim report including 
a summary of number of subjects enrolled by microfilaria strata, summary statistics of 
microfilaria counts pre-treatment and at each follow up time point completed up to 1 month prior 
to the date of the report (range, median, Williams geometric means for each microfilaria 
stratum), adverse events (number of adverse events by type, severity, seriousness separately 
for each microfilaria stratum). 
The same type of report will be generated 23 months after the initiation of the study unless at 
that time the study has been completed and a final study report (see section  12.10) has or will 
shortly be provided within the next 2 months. 
12.10 Final Study Report 
The clinical investigator will complete a report notifying the sponsor and the national authorities, 
if required, of the conclusion of the study within 2 weeks of the last follow up visit. A final report 
including all data analyses and conclusions will be sent to the TDR Product Manager within 3 
months of the last follow up visit.  
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12.11 Record retention 
The investigator will retain all study related records until 5 years after the publication of the 
results unless otherwise notified by the sponsor. 
12.12 Change in Investigator(s) 
If the principal investigator retires, relocates, or otherwise withdraws from conducting the study, 
the responsibility for maintaining records will be transferred to another investigator with the 
same qualifications. The sponsor and the National Ethics Committee will be notified of the 
change.  
12.13 Confidentiality 
All unpublished information that the sponsor gives to the investigators will be kept confidential 
and shall not be published or disclosed except to study personnel under the supervision of the 
investigator, Ethical Committees, or duly authorized representatives of regulatory agencies, 
under the condition that they maintain confidentiality. The investigator will not make a patent 
application based on the results of this study and will not assist any third party in making such 
an application without the written authorization of the sponsor, unless otherwise specified in the 
TSA. 
13 TERMINATION OF THE STUDY 
13.1 Termination by the Sponsor 
The sponsor may terminate the study at any time for any of the following reasons: 
1. Failure to enroll subjects. 
2. Protocol violations. 
3. Unsafe or unethical practices. 
4. Administrative decision. 
13.2 Termination by the Investigator 
If the investigator terminates the study prematurely, the investigator will provide a written 
statement to the sponsor and the National EC describing why the study was terminated 
prematurely.  The investigator will generate a report of the data obtained until the date of study 
termination. 
14 QUALITY ASSURANCE 
See section  12.8. 
15 PUBLICATIONS 
The investigators will target publication of the results in a recognized (refereed) scientific 
journal. The investigators will submit publications, reports, abstracts, manuscripts and/or other 
presentation materials to the sponsor for review prior to submission for publication or 
presentation. The sponsor shall have 60 calendar days to respond with any requested revisions, 
including without limitation, the deletion of confidential information. The investigators will act in 
good faith upon such requested revisions, except the investigators will delete any confidential 
information from such proposed publication or presentation.  
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17 ATTACHMENTS 
Informed Consent Information for Initial Screening (preliminary survey) 
Informed Consent Information for final subject qualification and study participation 
SAE Reporting Form 
SAE Form (Section 12, for follow up information) 
Pregnancy Notification Form 
Pregnancy Follow-Up Form - Current Pregnancy Information 
Protocol Amendment  
 
 Efficacy of albendazole in decreasing Loa loa microfilaraemia 
 
The protocol of the study on the Efficacy of albendazole in decreasing Loa loa microfilaraemia 
started in March 2007 in the south Province of Cameroon. This study which was a double 
blind study had to continue until 18 month (September 2008). The study continued to this term 
and the blind was lifted. Due to tendency of decrease in one of the group, it was proposed that 
the follow-up should continue to 24 months with two supplementary control of the Loa loa 
microfilaremia at M21 and M24. 
The procedure of blood sampling will remain as from M0 to M24. The blood sample will be 
collected almost and the same time, with the same material and with the same precautions. 
The examination of slides will follow the same procedures as the previous examinations. 
 
Signing of informed consent. 
Patients of the present trial signed an informed consent to participate at the study up to 18 
months. This trial was prolonged to 24 months. We will propose another informed consent to 
patients for the prolongation of the study. The objectives of this prolongation will be explained 
to all the patients and they will sign the third informed consent. They will be examined for the 
two last calibrated blood smears as at M14 and M18. 
 
Subject Compensation 
Subjects who accept to continue the study and who signs the informed consent will be 
compensated for any expenses incurred during the transport to the study site but will not have 
direct financial compensation for study participation. 
 
Information of the subjects of the study results  
During explanation for the continuation of the study, the investigators will explain the tendency 
of the LLM of each patient. This explanation will be completed when the final data from the 
study will be available. Each patient will be informed individually about the evolution of his Loa 
loa microfilaremia. 
